Ignyta, Inc., a San Diego, California-based personalized medicine company, received a $1m capital term loan facility from Silicon Valley Bank.
The new loan is additional to the previous $500K facility entered into between Ignyta and SVB in June 2012. The company also raised $5.5m Series B funding in 2013 (read here about the 2012 loan and the round).
Launched in August 2011 by CEO Jonathan E. Lim, M.D., and Gary S. Firestein, M.D., Ignyta applies “omics” technologies integrated with bioinformatics to the development and commercialization of novel biomarkers and tests for diagnostic and therapeutic applications in rheumatoid arthritis (RA), lupus and other autoimmune diseases.
FinSMEs
28/02/2013